ORGANIC LETTERS 2006

Vol. 8, No. 13 2699–2702

Synthesis of Cannabidiols via Alkenylation of Cyclohexenyl Monoacetate


Yuichi Kobayashi,* Akira Takeuchi, and Yong-Gang Wang

Department of Biomolecular Engineering, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8501, Japan

ykobayas@bio.titech.ac.jp

Received March 21, 2006

ABSTRACT



Because of the lack of potency binding to the receptors responsible for psychoactivity, cannabidiol has received much attention as a lead compound to develop a nonpsychotropic drug. Herein, we establish a method to access not only cannabidiol but also its analogues. The key reaction is nickel-catalyzed allylation of 2-cyclohexene-1,4-diol monoacetate with a new reagent, (alkenyl)ZnCl/TMEDA, which gives a S_N 2-type product with 94% regioselectivity in good yield.

After the finding of receptors $(CB_1)^1$ binding Δ^9 -tetrahydrocannabinol (Δ^9 -THC, **1**) (Figure 1),² biological study using cannabinoid analogues has led to the discovery of another subtype defined as CB_2 .³ Both receptors are now believed to be responsible for the psychoactivity triggered by cannabis preparations such as hashish and marijuana.⁴ In contrast to **1**, cannabidiol (CBD, **2**), another constituent of the cannabis preparations, does not bind to the receptors,⁵ and in

(3) Munro, S.; Thomas, K. L.; Abu-Shaar, M. *Nature* **1993**, *365*, 61–65.

(4) (a) Tullo, A. *Chem. Eng. News* **2005**, 83(25), 84. (b) Di Marzo, V.; Bifulco, M.; Petrocellis, L. D. *Nat. Rev. Drug Discovery* **2004**, *3*, 771– 784. (c) Palmer, S. L.; Thakur, G. A.; Makriyannis, A. *Chem. Phys. Lipids* **2002**, *121*, 3–19. (d) Kunos, G.; Bátkai, S.; Offertáler, L.; Mo, F.; Liu, J.; Karcher, J.; Harvey-White, J. *Chem. Phys. Lipids* **2002**, *121*, 45–56.

10.1021/ol060692h CCC: \$33.50 © 2006 American Chemical Society Published on Web 05/25/2006 consequence, **2** has received much attention as a lead compound to develop a nonpsychotropic drug. Moreover, recent studies have revealed other pharmacological properties such as antiinflammatory effects and activation of PPAR- γ .⁶ These aspects have created urgent demand for analogues as well as metabolites for further study.⁷

So far, **2** has been synthesized by several methods,^{8,9} among which the BF₃•OEt₂/Al₂O₃-promoted reaction^{9h} of the




Figure 1. Representative examples of cannabinoids.

^{(1) (}a) Devane, W. A.; Dysarz, F. A., III; Hohnson, M. R.; Melvin, L. S.; Howlett, A. C. *Mol. Pharmacol.* **1988**, *34*, 605–613. (b) Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonner, T. I. *Nature* **1990**, *346*, 561–564. (c) Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. *Science* **1992**, *258*, 1946–1949.

⁽²⁾ In this paper, two different numbering systems are adopted to indicate a specific site in the tricyclic and bicyclic cannabinoids to use the well-known abbreviations with the familiar numbers, for example, Δ^9 -THC (based on the dibenzopyran ring system) and 7-OH-CBD (based on the monoterpenoid system), etc.

Table 1.	Reaction of	Isopropenyl	Anions	with 1	Monoacetate	4 <i>a</i>
----------	-------------	-------------	--------	--------	-------------	-------------------

entry	reagent	reagent source (equiv)	additive(s) (equiv)	$\mathrm{catalyst}^b$	ratio ^{c} of 5a/11	yield, $\%^d$
1	7	6 (1.8), n-BuLi (2)	NaI (1), <i>t</i> -BuCN (5)	$NiCl_2(tpp)_2$	67:33	46^e
2	8	8 (4)	_	CuCN	60:40	81
3	8	8 (4)	$MgCl_2(15)$	CuCN	86:14	90
4	9	$8(4), ZnCl_2(10)$	_	CuCN	_	0
5	9	$8(4), ZnCl_2(10)$	_	$NiCl_2(tpp)_2$	67:33	31
6	9	$8(6), ZnCl_2(10)$	TMEDA (10)	$NiCl_2(tpp)_2$	92:8	95
7	9	$8(3.5), ZnCl_2(4)$	TMEDA (4.2)	$NiCl_2(tpp)_2$	94:6	85 (80) ^f
8	10	$8(6), ZnCl_2(2.5)$	TMEDA (2.5)	$NiCl_2(tpp)_2$	86:14	88

^{*a*} Reactions were carried out in THF at room temperature overnight (entries 1 and 4–8) or for 3 h (entries 2 and 3). ^{*b*} NiCl₂(tpp)₂ (20 mol %), CuCN (40 mol %). ^{*c*} Determined by ¹H NMR spectroscopy. ^{*d*} Combined yields determined by ¹H NMR spectroscopy with pyridine as a standard. ^{*e*} 2-Cyclohexenone was also coproduced in 15% yield. ^{*f*} Isolated yield.

monoterpene with olivetol furnished **2** in a satisfactory manner. However, the methods would hardly be applicable to synthesis of structurally related analogues, especially those possessing a longer alkenyl side chain in place of the isopropenyl group.^{4,10} A recent seven-step oxidation¹¹ of the C(7) methyl group of **2** producing 7-hydroxy-CBD (**3**), a metabolite of **2**, also implies the unavailability of a synthetic route to the CBD family.

Recently, we reported an indirect method for installation of a bulky aromatic ring onto the γ -substituted cyclohexenone and subsequent generation of a reactive enolate.¹² By using this method, we synthesized **1** and its analogues successfully. However, the substituent we could place at the γ position of the cyclohexanone is limited to that derived by aldol reaction with an aldehyde. To gain wider flexibility in this method, we envisaged reaction of 2-cyclohexene-1,4diol monoacetate **4**¹³ with alkenyl reagents furnishing compounds of type **5**, which would be transformed into the CBD family and related analogues by the method mentioned above (Scheme 1). A synthetic advantage of this strategy is availability of optically active **4** by the established method.¹³

(5) Mechoulam, R.; Hanus, L. *Chem. Phys. Lipids* 2002, *121*, 35–43.
(6) Sumariwalla, P. F.; Gallily, R.; Tchilibon, S.; Fride, E.; Mechoulam, R.; Feldmann, M. *Arthritis Rheum.* 2004, *50*, 985–998.

(7) Mechoulam, R.; Parker, L. A.; Gallily, R. J. Clin. Pharmacol. 2002, 42, 11S-19S.

(8) Tius, M. A. Stud. Nat. Prod. Chem. 1997, 19, 185-244.

(9) (a) Mechoulam, R.; Gaoni, Y. J. Am. Chem. Soc. 1965, 87, 3273–3275.
(b) Mechoulam, R.; Braun, P.; Gaoni, Y. J. Am. Chem. Soc. 1972, 94, 6159–6165.
(c) Vaillancourt, V.; Albizati, K. F. J. Org. Chem. 1992, 57, 3627–3631.
(d) Childers, W. E., Jr.; Pinnick, H. W. J. Org. Chem. 1984, 49, 5276–5277.
(e) Evans, D. A.; Barnes, D. M.; Johnson, J. S.; Lectka, T.; von Matt, P.; Miller, S. J.; Murry, J. A.; Norcross, R. D.; Shaughnessy, E. A.; Campos, K. R. J. Am. Chem. Soc. 1999, 121, 7582–7594.
(f) Petrzilka, T.; Haefliger, W.; Sikemeier, G.; Ohloff, G.; Eschenmoser, A. Helv. Chim. Acta 1967, 719–723.
(g) Razdan, R. K.; Dalzell, H. C.; Handrick, G. R. J. Am. Chem. Soc. 1974, 96, 5860–5865.
(h) Baek, S.-H.; Srebnik, M.; Mechoulam, R. Tetrahedron Lett. 1985, 26, 1083–1086.
(i) Hanus, L. O.; Tchilibon, S.; Ponde, D. E.; Breuer, A.; Fride, E.; Mechoulam, R. Org. Biomol. Chem. 2005, 3, 1116–1123.


(10) (a) Tius, M. A.; Busch-Petersen, J.; Marris, A. R. Chem. Commun. **1997**, 1867–1868. (b) Drake, D. J.; Jensen, R. S.; Busch-Petersen, J.; Kawakami, J. K.; Fernandez-Garcia, M. C.; Fan, P.; Makriyannis, A.; Tius, M. A. J. Med. Chem. **1998**, 41, 3596–3608. (c) Harrington, P. E.; Stergiades, I. A.; Erickson, J.; Makriyannis, A.; Tius, M. A. J. Org. Chem. **2000**, 65, 6576–6582. (d) Chu, C.; Ramamurthy, A.; Makriyannis, A.; Tius, M. A. J. Org. Chem. **2003**, 68, 55–61 and references therein.

(11) Tchilibon, S.; Mechoulam, R. Org. Lett. 2000, 2, 3301-3303.


(12) (a) William, A. D.; Kobayashi, Y. Org. Lett. **2001**, *3*, 2017–2020; J. Org. Chem. **2002**, 67, 8771–8782.

2700

Herein, we report a new reagent system for this purpose and a synthesis of 2 and CBD analogues.



The present investigation was started with an application of the reagent systems originally developed for cyclopentene monoacetate.¹⁴ Thus, reaction of **4** with lithium isopropenyl borate **7**,¹⁵ prepared in situ from the boronate ester **6** and *n*-BuLi, proceeded at room temperature but afforded a mixture of products, among which the desired product **5a** (R = Me) and the regioisomer **11** were detected in moderate yield with a 67:33 ratio by ¹H NMR spectroscopy (Table 1, entry 1). Next we studied the CuCN-catalyzed reaction with




alkenyl Grignard reagents. According to the earlier result with 2-cyclopentene-1,4-diol monoacetate, isopropenylmagnesium *chloride* would be a suitable reagent for the present reaction with 4.^{14c} However, preparation of the chloride reagent was unsuccessful as stated.^{14c} Instead, the *bromide* reagent 8, prepared easily, resulted in lower regioselectivity

(entry 2). The incompatibility between the reagent preparation and the regioselectivity was overcome by addition of excess MgCl₂, which afforded an improved ratio of 86:14 and a good combined yield (entry 3). In addition, separation of the regioisomers **5a** and **11** by silica gel column chromatography was an easy task.




Although the result of entry 3 might be practical, we next explored reaction with zinc reagents to attain a better selectivity. Thus, zinc reagent 9 (4 equiv), prepared from 8 and excess $ZnCl_2$, was subjected to reaction with 4 in the presence of CuCN or NiCl₂(tpp)₂ (tpp/PPh₃) as a catalyst (entries 4 and 5). Among the catalysts, NiCl₂(tpp)₂ afforded products **5a** and **11** but in lower regioselectivity and in lower yield. Fortunately, addition of TMEDA improved the regioselectivity and reactivity to afford **5a** in good yield (entry 6). Use of smaller quantities of the reagents and TMEDA also provided good results with 80% isolated yield (entry 7). In contrast, the reagent prepared from **8** and ZnCl₂ in a 2:1 ratio, probably **10**, was inferior in regioselectivity (entry 8).

Product 5a was transformed successfully into the dimethyl ether of CBD (Scheme 2). Oxidation of 5a afforded an enone, which underwent iodination at the α position by I₂ in the presence of 2,5-di-tert-butylhydroquinone (DBHQ) as a radical scavenger to produce α -iodo enone 14 in 63% yield (two steps). Addition of the 2,6-dimethoxy-4-pentylphenyl group (abbreviated as Ar in the scheme) to enone 14 was performed with the higher-order cyanocuprate 13 derived from the lithium anion 12 and CuCN according to our previous procedure¹² with modification.¹⁶ Compound **15**, obtained as a 1:1 stereoisomeric mixture at the α position, underwent reaction with EtMgBr¹⁷ to produce the reactive magnesium enolate, which was quenched with ClP(=O)- $(OEt)_2$ to furnish enol phosphate 16 in 51% yield from 14. Nickel-catalyzed coupling of 16 with MeMgCl afforded dimethyl ether 17 in good yield. The ¹H and ¹³C NMR spectra of synthetic 17 were identical with the data published.^{9c,i} Demethylation of **17** using MeMgI to CBD (**2**) and demethylation/cyclization to Δ^9 -THC (1) have been reported in the literature.9a,d



Synthesis of the dimethyl ether **19**, the known precursor of 7-hydroxy-CBD (**3**),^{9i,11} was achieved commencing with enol phosphate **16** as summarized in Scheme 3. Thus, nickel-




catalyzed reaction with ClMgCH₂Si(Me)₂(OPr-i) afforded the coupling product **18** in 80% yield, which upon Tamao oxidation¹⁸ produced alcohol **19**^{9i,11} in good yield.

We then turned our attention to the synthesis of analogues possessing a longer alkenyl chain in place of the isopropenyl group because the isopropenyl moiety is an important pharmacophore to control the biological property.^{4,10} The $CH_2=C(C_5H_{11})$ group was chosen as a typical example. Thus,

^{(13) (}a) Kazlauskas, R. J.; Weissfloch, A. N. E.; Rappaport, A. T.; Cuccia, L. A. J. Org. Chem. **1991**, *56*, 2656–2665. (b) Harris, K. J.; Gu, Q.-M.; Shih, Y.-E.; Girdaukas, G.; Sih, C. J. Tetrahedron Lett. **1991**, *32*, 3941–3944. (c) Bäckvall, J.-E.; Gatti, R.; Schink, H. E. Synthesis **1993**, 343–348. (d) López-Pelegrín, J. A.; Janda, K. D. Chem.–Eur. J. **2000**, *6*, 1917–1922. (e) Suzuki, H.; Yamazaki, N.; Kibayashi, C. J. Org. Chem. **2001**, *66*, 1494–1496. (f) Hua, Z.; Yu, W.; Su, M.; Jin, Z. Org. Lett. **2005**, *7*, 1939–1942.

^{(14) (}a) Review: Kobayashi, Y. *Curr. Org. Chem.* 2003, *7*, 133–147.
(b) Nakata, K.; Kobayashi, Y. *Org. Lett.* 2005, *7*, 1319–1322. (c) Kobayashi, Y.; Nakata, K.; Ainai, T. *Org. Lett.* 2005, *7*, 183–186. (d) Kobayashi, Y.; Murugesh, M. G.; Nakano, M.; Takahisa, E.; Usmani, S. B.; Ainai, T. J. Org. Chem. 2002, 67, 7110–7123.

⁽¹⁵⁾ The highly volatile nature of the isopropenyl boronate ester with the original 2,3-butanediol ligand prevented its isolation, whereas compound **6**, studied herein, was less volatile.



 $CH_2 = C(C_5H_{11})ZnCl$ (**20**) was prepared from $CH_2 = C(C_5H_{11})$ -MgBr and $ZnCl_2$ and subjected to reaction with monoacetate

4 in the presence of NiCl₂(tpp)₂ as a catalyst to afford **5b** in 86% yield with a 94:6 regioisomeric ratio¹⁹ (Scheme 4). Alcohol **5b** was converted to enol phosphate **23** in the same manner as **5a** was transformed to **16**. Finally, coupling of **23** with MeMgCl afforded **24**, and coupling with ClMgCH₂-Si(Me)₂(OPr-*i*) followed by Tamao oxidation¹⁸ of the resulting **25** furnished **26** in 60% yield over two steps.

In summary, we have developed a new way to prepare cannabinoids starting with monoacetate **4**, in which regioselective installation of an alkenyl group to the cyclohexenyl ring of **4** is accomplished with a new reagent system consisting of (alkenyl)ZnCl, TMEDA, and NiCl₂(tpp)₂ (cat.). Application of this reagent to other allylic substrates is under investigation.

Acknowledgment. This work was supported by a Grantin-Aid for Scientific Research from the Ministry of Education, Science, Sports, and Culture, Japan.

Supporting Information Available: Experimental procedures and spectral data for compounds described herein. This material is available free of charge via the Internet at http://pubs.acs.org.

OL060692H

⁽¹⁶⁾ Because we had occasionally experienced insufficient lithiation of the dimethyl ether of olivetol (Ar–H in Scheme 2) with *n*-BuLi in Et₂O, thus producing a mixture of **15** and the Bu group incorporated product **i**, we reinvestigated this step with or without any additive. We now recommend a procedure of stirring the olivetol ether (Ar–H) in Et₂O with *n*-BuLi (1.2 equiv) and DME (2.4 equiv) at room temperature for 2 h. Other conditions attempted are presented in the Supporting Information.



(17) Aoki, Y.; Oshima, K.; Utimoto, K. *Chem. Lett.* **1995**, 463–464. (18) Tamao, K.; Ishida, N. *Tetrahedron Lett.* **1984**, *25*, 4245–4248.

(19) Taniao, K., Isinda, N. Tertanearon Lett. **1964**, 25, 425, 4248. (19) The reagent system with $CH_2=CH(C_5H_{11})MgBr$ (3.5 equiv), CuCN (30 mol %), and MgCl₂ (10 equiv) in THF afforded a 77:23 mixture of **5b** and its regioisomer quantitatively.